Objective: Levosimendan is a calcium-sensitising inotropic agent and a vasodilator used in the treatment of heart failure. Post-cardiotomy cardiac failure is more common in patients with a low preoperative left ventricular ejection fraction (LVEF). We aim at investigating how prophylactic treatment with levosimendan before weaning from cardiopulmonary bypass (CPB) affects postoperative haemodynamics and outcome in patients with low preoperative LVEF. Methods: Patients with a preoperative LVEF 30% treated with levosimendan before weaning from CPB were included in the study. Each patient was matched to a control patient with respect to the following criteria: surgical procedure, EuroSCORE, age, gender and the use of intra-aortic balloon pump. We investigated postoperative haemodynamics in the intensive care unit (ICU) at time points: 1, arrival; 2, approximately 7 h after arrival; and 3, the first postoperative morning. In addition, mortality was evaluated. Results: Thirty patients treated with levosimendan and 30 matched controls were enrolled in the study. No statistically significant differences in cardiac index (CI) (l min À1 m À2 ), stroke volume index (SVI) (ml m À2 ), mixed venous O 2 -saturation (SvO 2 ) (%) or heart rate (HR) (beats per minute) between the two groups measured at the three time points 1-3 were registered. Mean arterial blood pressure (MAP) (mmHg) was lower in the levosimendan group both at time points 2 (68, range: 65-71 vs 75, range: 72-78; p = 0.009) and 3 (72, range: 69-74 vs 78, range: 74-82; p = 0.01), despite a higher dose of norepinephrine in the treatment group ( p = 0.021). A significantly higher number of control patients were treated with classic adrenergic inotropes both in the operating room ( p = 0.013) and in the ICU ( p < 0.001). Thirty days mortality was the same in both groups (7%). Conclusions: Prophylactic infusion of levosimendan initiated before weaning from CPB did not lead to superior haemodynamic parameters (CI, SVI, SvO 2 ) compared to controls. Levosimendan reduced MAP and increased the need for norepinephrine postoperatively. #
Introduction
Commonly used inotropic agents, such as beta-adrenergic agonists and phosphodiesterase inhibitors, exert their effects by increasing myocardial cyclic 3 0 ,5 0 -adenosine monophosphate (cAMP) concentration, thus amplifying the intracellular calcium transients. The increasing Ca 2 transients augment the oxygen consumption of the myocyte [1] . Unfortunately, most inotropic agents are associated with adverse side effects [2, 3] , for example, arrhythmias, and have been shown to increase mortality in patients with decompensated heart failure [4] .
Levosimendan's main mechanism of action is proposed to be calcium sensitising of troponin C [5] . This increases myocardial contractility with minimal increase in calcium transients and oxygen consumption [6] . Through opening of K + channels on the arterial myocytes [7] , levosimendan has vasodilatory effects resulting in reduced systemic arterial pressure [8] . Furthermore, levosimendan has been shown to increase coronary flow reserve [9] and is thought to have a preconditioning effect through opening of mitochondrial ATP-sensitive K + channels [10, 11] . Patients with poor preoperative cardiac function are susceptible for post-cardiotomy low cardiac output syndrome (LOS), and temporary inotropic support may be necessary. Due to its unique mechanism of action, levosimendan has been used prophylactically to prevent post-cardiotomy heart failure in patients with impaired preoperative heart function.
The aim of our study was to investigate how prophylactic treatment with levosimendan before attempting to wean from cardiopulmonary bypass (CPB) affects postoperative haemodynamics and mortality in patients with preoperative reduced left ventricular function. We retrospectively compared patients, who received levosimendan, with matched controls, who were only treated with classic adrenergic agents inotropes.
Material and methods

Patient population
Patients were retrospectively identified from our cardiac surgical database, using data collected from January 2000 to November 2007. In this period, a total number of 5004 patients underwent open-heart surgery in our hospital. Patients with preoperative left ventricular ejection fraction (LVEF) 30% who received prophylactic levosimendan before weaning from CPB were assigned to the treatment group. Each treatment patient was individually matched to another patient. From our database, including all patients operated during the study period, we selected all patients with an EF 30% who did not receive levosimendan during the hospital stay. These patients formed the basis of the control group. Thereafter, we tried to find the perfect match according to the following criteria: postoperative use of intra-aortic balloon pump (IABP), main category of operative procedure, EuroSCORE, gender and age. We managed to match all patients perfectly with respect to IABP use and main categories of operative procedure (1) coronary artery bypass grafting (CABG), (2) valve replacement/-reconstruction and (3) combined procedure. When weighing the remaining characteristics, we considered EuroSCORE (which comprises scoring for age and gender) as more important than age and gender. The matching process was done without knowledge of the final outcome of the patients. These criteria and the matching process resulted in a study population of 60 patients (n = 30 both in the treatment and the control group).
Surgical technique
The patients followed our standard anaesthetic regimen. All medication except angiotensin-converting enzyme (ACE) inhibitors/AII blockers was maintained until surgery, including beta-adrenergic blockers. Age-and weight-related doses of morphine-scopolamine were given for premedication. Anaesthesia was induced with diazepam, pentothal, fentanyl and pancuronium and maintained with isoflurane and supplements of fentanyl up to a total dose of 10 mg kg À1 . Propofol was used for sedation during CPB and postoperatively until extubation. Morphine was given for postoperative analgesia. CPB employed standard-membrane oxygenator, Alphastat-blood-gas control, pump flow of 2.4 l m À2 , venous temperature 34-36 8C and mean arterial blood pressure between 50 and 70 mmHg.
CPB was employed in all cases. Before CPB, heparin 300 U kg À1 (Leo, Copenhagen, Denmark) was given through a central venous line to achieve a kaolin activated clotting time (ACT) of >480 s. Additional heparin was given when needed to keep the ACT above 480 s. The perfusion circuit was primed with 1800 ml of Ringer's acetate solution, to which 7500 U of heparin was added. Cold crystalloid or blood cardioplegia and moderate hypothermia (32-34 8C) were employed during CPB. Cardiotomy suction was used while the patients were fully anticoagulated. The patients were warmed to a rectal temperature of at least 36 8C before termination of CPB. After CPB, protamine sulphate was used as needed to reverse the heparin effect. Blood remaining in the CPB circuit was collected and transfused to the patients.
A standardised surgical technique was used in all patients. Coronary surgery was performed with a left internal mammary graft to the left anterior descending coronary artery in all patients where the left anterior descending artery was bypassed. Aortocoronary vein grafts were constructed to all other territories. Distal anastomoses were constructed first and proximal anastomoses were sewn with the use of a partial aortic clamp. In cases with combined procedures, distal coronary anastomoses were done before the valve procedure. Valve procedures and other operations were performed according to standard techniques.
A fast-track extubation and mobilisation policy was followed postoperatively.
Monitoring, measurements and recordings
Preoperative LVEF was assessed by left ventricular (LV) ventriculography (preferred) or echocardiography if no preoperative ventriculography was available. Intra-and postoperatively, patients were monitored with standard five-lead electrocardiogram (ECG) and invasive blood pressures (arterial, central venous and pulmonary artery pressures). The mixed venous O 2 -saturation (SvO 2 ) (%) was either monitored continuously by reflectance oximetry pulmonary artery catheter or intermittently from blood samples from a standard pulmonary artery catheter. Furthermore, cardiac index (CI) (l min À1 m À2 ) was measured by thermodilution either continuously or by intermittent bolus technique. Most patients in both the groups were evaluated intermittently (16 (64%) patients in the levosimendan group and 20 (69%) in the control group). When an intermittent technique was used, three individual measurements were used to calculate the mean. Measurements of SvO 2 , CI, heart rate (HR) (beats per minute) and mean arterial blood pressure (MAP) (mmHg) from our patient population are reported at (1) the time of arrival at intensive care unit (ICU), (2) approximately 7 h after arrival at ICU and (3) the first postoperative morning. Stroke volume index (SVI) (ml m À2 ) is calculated from CI and HR at the same time points. Serum creatine kinase-myocardial band (CKMB), creatinine and C-reactive protein (CRP) were measured daily during ICU treatment using standard laboratory methods. Haemoglobin was measured more frequently using blood gas measurement methods.
To compare treatment with vasopressors and inotropic agents other than levosimendan in both the groups, drug charts for the first 24 h were studied.
Statistical analyses
All statistical tests were performed in SPSS 15.0. The distribution of the differences between the two groups (the end-point/characteristic of the levosimendan patient minus the end-point/characteristic of the control patient) was assessed by the q-q plot function. Variables are presented as mean and 95% confidence interval in brackets, and have been analysed with paired Student's t-test when they are normally distributed. When having a skewed/non-parametric distribution, the variables are presented as median and 95% confidence interval in brackets, and have been analysed with the Wilcoxon signed-rank test. When comparing proportions, the McNemar test was used. Ordinal data were compared using the marginal homogeneity test for matchedordered categorical data, with exact p-value calculated in StatXact. With a power of 80%, and considering any change in SVI, CI, SvO 2 , HR and MAP higher than 20% as clinical significant, we calculated that with one exception (SVI the first postoperative morning), the study had data from a sufficient number of patients to find any statistical clinically significant differences ( p < 0.05).
Results
Patient characteristics
Pre-, peri-and postoperative characteristics are summarised in Tables 1 and 2 . The patients' preoperative risk profiles were analysed with regard to NYHA, ASA, urgency of surgery and EuroSCORE. There were no significant differences between the two groups. Furthermore, intra-operative characteristics such as aortic cross-clamp time (ACC), time on CPB and lactate values (before, during and after CPB) were the same in both groups. Postoperatively, levosimendan patients had a statistically significant longer stay in the ICU, though both the groups had a median ICU stay of 1 day. No effects of levosimendan on postoperative lactate, creatinine, CKMB and frequency of multiple-organ failure were found.
Levosimendan treatment
The infusion of levosimendan was started preoperatively (n = 2) or in the operating room (OR) (n = 28). Three of the patients were given a bolus before constant infusion. The mean duration of levosimendan infusion was 17.8 AE 4.5 h. The minimum infusion time was 11.5 h and maximum infusion time was 33.5 h. The mean dose in the OR and at arrival in the ICU was 0.18 AE 0.04 mg kg À1 min À1 . During the period of infusion in the OR and in the ICU, the minimum dose was 0.08 mg kg À1 min À1 and the maximum dose was 0.27 mg kg À1 min À1 . All patients received at least a total dose of 12.5 mg.
Haemodynamics
The haemodynamic indices are given in Fig. 1 and Table 3 . Our three main haemodynamic end-points related to heart pump function (CI, SVI and SvO 2 ), measured at the three time points 1-3, were not significantly different between the two groups studied. However, MAP was significantly lower in the levosimendan group at time points 2 and 3, which may indicate a vasodilator effect of levosimendan.
Treatment with norepinephrine and alternative inotropic agents
Use of other inotropic agents and vasopressors given in the OR and the first 24 h in the ICU are presented in Fig. 2 Columns show percentage of patients in each group who received norepinephrine (NE) or beta-adrenergic inotropes in the operating room (OR) or intensive care unit (ICU). **Statistically significant inter-group difference in proportion given the drug p < 0.01. ***Statistically significant inter-group difference in proportion given the drug p < 0.001. the ICU, levosimendan patients received a mean dose of 0.09 AE 0.06 mg kg À1 min À1 , while the control patients received a mean dose of 0.02 AE 0.05 mg kg À1 min
À1
. This difference was statistically significant ( p = 0.021).
Thirty days mortality
The 30 days all-cause mortality was two of 30 patients (7%) in both the groups. This number is less than expected from the logistic EuroSCORE 95% confidence interval within both the groups (Table 1) .
Discussion
The main aim of this retrospective matched-control study was to evaluate whether postoperative haemodynamics were affected by prophylactic use of levosimendan in patients with EF 30% undergoing open-heart surgery. The three main haemodynamic end-points (CI, SVI and SvO 2 ) were not significantly different between the levosimendan and the control groups. Furthermore, mortality and the frequency of other major complications were not different between the two groups. This indicates that levosimendan, given prophylactically to patients with reduced left ventricular function, is not superior to beta-adrenergic inotropes, when it concerns improving postoperative haemodynamics and outcome.
Numerous uncontrolled case series have indicated that levosimendan results in increased CI and reduced pulmonary capillary wedge pressure (PCWP) when given alone or in combination with catecholamines [12] [13] [14] [15] . When compared to placebo, levosimendan increased cardiac output at unaltered myocardial oxygen consumption and without increase in arrhythmias [16, 17] . However, these placebo-controlled trials are not directly comparable to our study, which compares levosimendan to beta-adrenergic inotropes in patients with preoperatively impaired left ventricular function.
Two randomised controlled studies have investigated the difference between levosimendan and the phosphodiesteraseinhibitor milrinone. In a study of 30 patients with preoperatively impaired left ventricular function and established LOS after heart surgery, levosimendan-treated patients had significantly higher CI and SvO 2 compared to the group that received milrinone [18] . Although there was a tendency towards shorter time on ventilatory support, shorter ICU stay and less renal dysfunction in the levosimendan group, this was not statistically significant. Mortality was similar in the two groups [18] . De Hert et al. have published a prospective randomised study of 30 patients with a LVEF 30% who received either levosimendan and dobutamine or milrinone and dobutamine [19] . In contrast to our work, De Hert showed that levosimendan resulted in a higher postoperative SVI compared to controls. In addition, intubation time and total duration of inotropic support was shorter in the levosimendan group. Three patients died in the milrinone group, but none in the levosimendan group. The latter was not statistically significant. The differences between these two publications and our study could be explained in several ways. Both De Hert's and Al-Shawaf's study had a randomised design and included a smaller number of patients than our work. Both investigators compared levosimendan to milrinone, a drug not used in our trial. Al-Shawaf included patients with established LOS only, while we administered levosimendan as a prophylaxis against LOS. In De Hert's investigation, type of procedure, ventricular function, timing of infusion and preoperative EuroSCORE were similar to our study. However, De Hert et al. combined levosimendan with dobutamine, whereas most patients in our treatment group received levosimendan only as an inotrope. Nevertheless, the most important differences seem to lie in the outcome of patients in the control groups. Whereas levosimendan patients in our study had haemodynamics remarkably similar to levosimendan-treated patients in De Hert's study, their controls had inferior haemodynamics compared to our controls. Moreover, substantially longer time on CPB and longer ACC duration were reported by De Hert compared to our results.
All our patients had preoperatively impaired LV function and received levosimendan intra-operatively (before attempting to wean from CPB) as a prophylaxis against LOS. Given the possible preconditioning properties of levosimendan, timing of administration could be an important issue when evaluating outcome. This issue has been addressed by several [22] . Patients were randomised to receive levosimendan or placebo 24 h before surgery. The levosimendan-treated patients had significantly lower frequency of postoperative LOS (6.3% vs 18.2%, p < 0.05) and lower mortality (2.7% vs 10.9%, p < 0.05). These three studies were not designed to answer the questions we asked in our study. However, they do address the issue of timing, and point towards timing as a possible explanation for differences between our investigation and other, comparable, studies.
In our study, there was no difference in 30 days mortality between the levosimendan-treated patients and controls. There is conflicting evidence regarding levosimendan's impact on mortality in a cardiac surgical setting. We have already mentioned a few studies that failed to show any survival benefit of levosimendan, and in our trial, mortality was identical in the two groups. In contrast, a retrospective study on patients with LOS needing catecholamines and mechanical circulatory support showed that the levosimendan-treated patients had significantly higher long-term survival (seven out of nine patients compared to three out of 29 patients at 180 days after surgery, p < 0.002). There was also a tendency towards higher short-term survival and fewer complications in the levosimendan group [23] .
In a retrospective matched-pair analysis by Lehman et al. [24] of high-risk patients undergoing CABG, 25 patients received catecholamines and 27 matched patients received catecholamines and levosimendan. The levosimendan group had fewer IABP insertions and less need for renal replacement therapy. However, this decrease of morbidity did not translate into reduced length of stay or mortality. In a recent publication, Levin et al. presented a prospective study of 137 patients with LOS after CABG, randomised to receive levosimendan or dobutamine within 6 h after surgery [25] . The levosimendan-treated patients had significantly higher CI and SvO 2 up to 48 h after surgery. Furthermore, the levosimendan-treated patients had lower frequency of major complications such as renal failure, ventricular arrhythmias, sepsis and prolonged ventilatory assistance. Most interestingly, mortality in the levosimendan group was lower (8.7% vs 25.0%, p < 0.05).
Before concluding, it is important to review what we actually have investigated. It should be appreciated that this is a study of a largely unselected group of patients whose only common characteristics are that they are scheduled for cardiac surgery and have a preoperatively impaired left ventricular function. Furthermore, this is a study of prophylactic use and does not address the use of levosimendan as a bailout treatment in desperate clinical situations.
From the findings in our investigation, we can only conclude that routinely administering levosimendan prophylactically to a largely unselected patient population with EF less than 30% does not seem to have any advantages over catecholamines.
Conclusion
The lack of differences in CI, SVI and SvO 2 between the two groups in this study does not support the prophylactic use of levosimendan over beta-adrenergic inotropic agents in open-heart surgery patients with a low preoperative LVEF.
